XOMA — Xoma Royalty Share News
0.000.00%
Last trade - 00:00- $792.01m
- $808.75m
- $52.15m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Deals of the day-Mergers and acquisitions
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million (updated)
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
NASDAQ RESUMED AT 08:05 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Ligand Pharmaceuticals Is Buying Xoma For Nearly $740 Million - WSJ
XOMA 2025 income, revenue jump on portfolio expansion, milestone payments
Brief: XOMA FY EPS USD 1.46
Brief: Xoma Royalty Announces CFO Transition
Brief: Xoma Royalty And Takeda Execute Strategic Royalty Sharing Transaction And Amend Existing Agreement For Mezagitamab
Brief: Xoma Royalty Enters Into Agreement To Acquire Generation Bio
Brief: Xoma Royalty Announces Closing Of Transaction To Acquire Mural Oncology PLC